Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Wabash National (NYSE: WNC) reported first quarter EPS of $-0.58, $0.32 worse than the analyst estimate of $-0.26. Revenue for the quarter came in at $381M versus the consensus estimate of $414.55M.
Guidance
Wabash National sees Q2 2025 EPS of $-0.60-$0.00 versus the analyst consensus of $0.59.
Wabash National sees Q2 2025 revenue of $1.80B versus the analyst consensus of $1.87B.
Wabash National’s stock price closed at $9.96. It is down -36.15% in the last 3 months and down -56.10% in the last 12 months.
Wabash National saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Wabash National’s stock price’s past reactions to earnings here.
According to InvestingPro, Wabash National’s Financial Health score is "fair performance".
Check out Wabash National’s recent earnings performance, and Wabash National’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar